ArticleHepatobiliary surgery and nutrition2026
Monitoring with plasma apolipoprotein A2-isoforms can predict developing new-onset steatotic liver disease caused by pancreatic exocrine insufficiency following pancreatectomy.
Article in Hepatobiliary surgery and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Development of new-onset steatotic liver disease (SLD) has been increasingly observed after pancreatectomy. However, the pathophysiology of post-operative SLD remains poorly understood. This study aimed to clarify the risk factors for new-onset SLD after pancreatectomy and verify the utility of monitoring plasma apolipoprotein A2-isoforms (apoA2-i) as a potentially promising biomarker for evaluating pancreatic exocrine function. Methods: In this retrospective study of 79 patients who underwent pancreatectomy [47 pancreaticoduodenectomies (PDs) and 32 distal pancreatectomies (DPs)] between March 2021 and March 2024, the plasma apoA2-i (AT/AT and ATQ/ATQ) levels were measured using enzyme-linked immunosorbent assay (ELISA) methods, and non-contrast-enhanced computed tomography (CT) images were manually reviewed for the diagnosis of SLD. Results: Comparing the minimum value of apoA2-AT/AT after surgery between the SLD (n=32) and non-SLD group (n=47), the apoA2-AT/AT value in the SLD group was significantly lower than that in the non-SLD group (P<0.001). The plasma apoA2-AT/AT levels <9.58 µg/mL (median of this cohort) was significantly associated with SLD (P<0.001) and an independent risk factor of SLD with both univariable [odds ratio (OR), 20.1; 95% confidence interval (CI): 6.59-74.5; P<0.001] and multivariable (OR, 13.6; 95% CI: 2.68-134.2; P=0.001) logistic regression analysis. Moreover, even when stratified by pre-onset pancrelipase administration, the cumulative incidence of SLD was significantly higher in patients with plasma apoA2-AT/AT levels <9.58 µg/mL (P<0.001). The point estimate of the area under the curve for detecting SLD of apoA2-AT/AT was 0.843. Conclusions: SLD associated with malnutrition following pancreatectomy can be predicted using plasma apoA2-i monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.